Armata Pharmaceuticals Inc (NYSE MKT:ARMP) — Market Cap & Net Worth
Market Cap & Net Worth: Armata Pharmaceuticals Inc (ARMP)
Armata Pharmaceuticals Inc (NYSE MKT:ARMP) has a market capitalization of $284.70 Million ($284.70 Million) as of May 11, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #15211 globally and #3415 in its home market, demonstrating a -16.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Armata Pharmaceuticals Inc's stock price $8.30 by its total outstanding shares 36406905 (36.41 Million). Analyse ARMP cash flow conversion to see how efficiently the company converts income to cash.
Armata Pharmaceuticals Inc Market Cap History: 2015 to 2026
Armata Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $20.29 Billion to $302.18 Million (-35.67% CAGR).
Armata Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Armata Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.02x
Armata Pharmaceuticals Inc's market cap is 13.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $20.29 Billion | $475.00K | -$516.00K | 42707.22x | N/A |
| 2016 | $2.24 Billion | $260.00K | -$18.84 Million | 8625.64x | N/A |
| 2017 | $514.79 Million | $115.00K | -$12.84 Million | 4476.47x | N/A |
| 2019 | $118.32 Million | $31.00K | -$19.48 Million | 3816.85x | N/A |
| 2020 | $108.49 Million | $823.00K | -$22.18 Million | 131.83x | N/A |
| 2021 | $199.51 Million | $4.47 Million | -$23.16 Million | 44.59x | N/A |
| 2022 | $45.14 Million | $5.51 Million | -$36.92 Million | 8.20x | N/A |
| 2023 | $117.96 Million | $4.53 Million | -$69.05 Million | 26.05x | N/A |
| 2024 | $67.35 Million | $5.17 Million | -$18.92 Million | 13.02x | N/A |
Competitor Companies of ARMP by Market Capitalization
Companies near Armata Pharmaceuticals Inc in the global market cap rankings as of May 11, 2026.
Key companies related to Armata Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.05 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #360 globally with a market cap of $74.28 Billion USD.
- UCB SA (BR:UCB): Ranked #510 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #569 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.05 Billion | $429.82 |
| #360 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.28 Billion | $714.89 |
| #510 | UCB SA | BR:UCB | $51.74 Billion | €234.10 |
| #569 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Armata Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Armata Pharmaceuticals Inc's market cap moved from $20.29 Billion to $ 302.18 Million, with a yearly change of -35.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $302.18 Million | +32.17% |
| 2025 | $228.64 Million | +239.46% |
| 2024 | $67.35 Million | -42.90% |
| 2023 | $117.96 Million | +161.29% |
| 2022 | $45.14 Million | -77.37% |
| 2021 | $199.51 Million | +83.89% |
| 2020 | $108.49 Million | -8.31% |
| 2019 | $118.32 Million | +10.54% |
| 2018 | $107.04 Million | -79.21% |
| 2017 | $514.79 Million | -77.05% |
| 2016 | $2.24 Billion | -88.94% |
| 2015 | $20.29 Billion | -- |
End of Day Market Cap According to Different Sources
On May 10th, 2026 the market cap of Armata Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $284.70 Million USD |
| MoneyControl | $284.70 Million USD |
| MarketWatch | $284.70 Million USD |
| marketcap.company | $284.70 Million USD |
| Reuters | $284.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudo… Read more